<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">37369876</PMID><DateCompleted><Year>2023</Year><Month>09</Month><Day>12</Day></DateCompleted><DateRevised><Year>2023</Year><Month>09</Month><Day>22</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1590-3478</ISSN><JournalIssue CitedMedium="Internet"><Volume>44</Volume><Issue>10</Issue><PubDate><Year>2023</Year><Month>Oct</Month></PubDate></JournalIssue><Title>Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology</Title><ISOAbbreviation>Neurol Sci</ISOAbbreviation></Journal><ArticleTitle>Phosphorylated tau in plasma could be a biomarker of lower motor neuron impairment in amyotrophic lateral sclerosis.</ArticleTitle><Pagination><StartPage>3697</StartPage><EndPage>3702</EndPage><MedlinePgn>3697-3702</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1007/s10072-023-06916-4</ELocationID><Abstract><AbstractText Label="INTRODUCTION" NlmCategory="BACKGROUND">Plasma levels of phosphorylated tau (P-tau181) have been recently reported to be increased in amyotrophic lateral sclerosis (ALS) and associated with lower motor neuron (LMN) impairment.</AbstractText><AbstractText Label="PATIENTS AND METHODS" NlmCategory="METHODS">We quantified plasma P-tau181 (pP-tau181) in a cohort of 29 deeply phenotyped ALS patients using the new fully automated Lumipulse assay and analysed phenotype-biomarker correlations.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">pP-tau181 levels correlated positively with a clinical LMN score (r&#x2009;=&#x2009;0.3803) and negatively, albeit not significantly, with a composite index of muscle strength (r&#x2009;=&#x2009;&#x2009;-&#x2009;0.3416; p&#x2009;=&#x2009;0.0811), but not with Penn Upper Motor Neuron (UMN) Score. Accordingly, pP-tau181 correlated with electromyographic indices of spinal active and chronic denervation (r&#x2009;=&#x2009;0.4507 and r&#x2009;=&#x2009;0.3864, respectively) but not with transcranial magnetic stimulation parameters of UMN dysfunction. pP-tau181 levels did not correlate with those in the cerebrospinal fluid (CSF), serum NFL, serum GFAP, CSF/serum albumin ratio, or estimated glomerular filtration rate, but correlated with plasma creatine kinase levels (r&#x2009;=&#x2009;0.4661). Finally, while not being associated with neuropsychological phenotype, pP-tau181 correlated negatively with pH (r&#x2009;=&#x2009;&#x2009;-&#x2009;0.5632) and positively with partial pressure of carbon dioxide (PaCO<sub>2</sub>; r&#x2009;=&#x2009;0.7092), bicarbonate (sHCO<sub>3</sub><sup>-</sup>; r&#x2009;=&#x2009;0.6667) and base excess (r&#x2009;=&#x2009;0.6611) on arterial blood gas analysis.</AbstractText><AbstractText Label="DISCUSSION" NlmCategory="CONCLUSIONS">pP-tau181 has potential as ALS biomarker and could be associated with LMN impairment. Its raised levels might reflect pathophysiological processes (tau hyperphosphorylation and/or release) occurring in the axons of LMNs distantly from the CNS and the CSF. pP-tau181 could also be associated with respiratory dysfunction.</AbstractText><CopyrightInformation>&#xa9; 2023. Fondazione Societ&#xe0; Italiana di Neurologia.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Verde</LastName><ForeName>Federico</ForeName><Initials>F</Initials><Identifier Source="ORCID">0000-0002-3977-6995</Identifier><AffiliationInfo><Affiliation>Department of Neurology and Laboratory of Neuroscience, IRCCS Istituto Auxologico Italiano, Piazzale Brescia, 20 - 20149, Milan, Italy. f.verde@auxologico.it.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Pathophysiology and Transplantation, Dino Ferrari Center, Universit&#xe0; Degli Studi Di Milano, Milan, Italy. f.verde@auxologico.it.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Milone</LastName><ForeName>Ilaria</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Department of Neurology and Laboratory of Neuroscience, IRCCS Istituto Auxologico Italiano, Piazzale Brescia, 20 - 20149, Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Colombo</LastName><ForeName>Eleonora</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Department of Neurology and Laboratory of Neuroscience, IRCCS Istituto Auxologico Italiano, Piazzale Brescia, 20 - 20149, Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Maranzano</LastName><ForeName>Alessio</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Neurology and Laboratory of Neuroscience, IRCCS Istituto Auxologico Italiano, Piazzale Brescia, 20 - 20149, Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dubini</LastName><ForeName>Antonella</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Laboratory of Clinical Chemistry and Microbiology, Department of Laboratory Medicine, IRCCS Istituto Auxologico Italiano, Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Colombrita</LastName><ForeName>Claudia</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Laboratory of Clinical Chemistry and Microbiology, Department of Laboratory Medicine, IRCCS Istituto Auxologico Italiano, Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gentile</LastName><ForeName>Francesco</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Neurology Residency Program, Universit&#xe0; Degli Studi Di Milano, Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Doretti</LastName><ForeName>Alberto</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Neurology and Laboratory of Neuroscience, IRCCS Istituto Auxologico Italiano, Piazzale Brescia, 20 - 20149, Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Torre</LastName><ForeName>Silvia</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Neurology and Laboratory of Neuroscience, IRCCS Istituto Auxologico Italiano, Piazzale Brescia, 20 - 20149, Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Messina</LastName><ForeName>Stefano</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Neurology and Laboratory of Neuroscience, IRCCS Istituto Auxologico Italiano, Piazzale Brescia, 20 - 20149, Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Morelli</LastName><ForeName>Claudia</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Neurology and Laboratory of Neuroscience, IRCCS Istituto Auxologico Italiano, Piazzale Brescia, 20 - 20149, Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Torresani</LastName><ForeName>Erminio</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Laboratory of Clinical Chemistry and Microbiology, Department of Laboratory Medicine, IRCCS Istituto Auxologico Italiano, Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Poletti</LastName><ForeName>Barbara</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Department of Neurology and Laboratory of Neuroscience, IRCCS Istituto Auxologico Italiano, Piazzale Brescia, 20 - 20149, Milan, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Oncology and Hemato-Oncology, Universit&#xe0; Degli Studi Di Milano, Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Priori</LastName><ForeName>Alberto</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Aldo Ravelli Research Center for Neurotechnology and Experimental Neurotherapeutics, Department of Health Sciences, Universit&#xe0; Degli Studi Di Milano, Milan, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>III Neurology Clinic, ASST Santi Paolo E Carlo University Hospital, Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Maderna</LastName><ForeName>Luca</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Neurology and Laboratory of Neuroscience, IRCCS Istituto Auxologico Italiano, Piazzale Brescia, 20 - 20149, Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ratti</LastName><ForeName>Antonia</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Neurology and Laboratory of Neuroscience, IRCCS Istituto Auxologico Italiano, Piazzale Brescia, 20 - 20149, Milan, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Medical Biotechnology and Translational Medicine, Universit&#xe0; Degli Studi Di Milano, Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Silani</LastName><ForeName>Vincenzo</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Department of Neurology and Laboratory of Neuroscience, IRCCS Istituto Auxologico Italiano, Piazzale Brescia, 20 - 20149, Milan, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Pathophysiology and Transplantation, Dino Ferrari Center, Universit&#xe0; Degli Studi Di Milano, Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ticozzi</LastName><ForeName>Nicola</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Department of Neurology and Laboratory of Neuroscience, IRCCS Istituto Auxologico Italiano, Piazzale Brescia, 20 - 20149, Milan, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Pathophysiology and Transplantation, Dino Ferrari Center, Universit&#xe0; Degli Studi Di Milano, Milan, Italy.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>06</Month><Day>27</Day></ArticleDate></Article><MedlineJournalInfo><Country>Italy</Country><MedlineTA>Neurol Sci</MedlineTA><NlmUniqueID>100959175</NlmUniqueID><ISSNLinking>1590-1874</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015415">Biomarkers</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016875">tau Proteins</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="Y">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009046" MajorTopicYN="N">Motor Neurons</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015415" MajorTopicYN="N">Biomarkers</DescriptorName><QualifierName UI="Q000134" MajorTopicYN="N">cerebrospinal fluid</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016875" MajorTopicYN="N">tau Proteins</DescriptorName><QualifierName UI="Q000134" MajorTopicYN="N">cerebrospinal fluid</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Amyotrophic lateral sclerosis (ALS)</Keyword><Keyword MajorTopicYN="N">Biomarker</Keyword><Keyword MajorTopicYN="N">Lower motor&#xa0;neuron (LMN)</Keyword><Keyword MajorTopicYN="N">Phosphorylated tau (P-tau181)</Keyword><Keyword MajorTopicYN="N">Plasma</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>5</Month><Day>9</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>6</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>9</Month><Day>12</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>6</Month><Day>28</Day><Hour>1</Hour><Minute>6</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>6</Month><Day>27</Day><Hour>23</Hour><Minute>29</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37369876</ArticleId><ArticleId IdType="doi">10.1007/s10072-023-06916-4</ArticleId><ArticleId IdType="pii">10.1007/s10072-023-06916-4</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Cousins KAQ, Shaw LM, Shellikeri S et al (2022) Elevated plasma phosphorylated tau 181 in amyotrophic lateral sclerosis. Ann Neurol 92(5):807&#x2013;818. https://doi.org/10.1002/ana.26462</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.26462</ArticleId><ArticleId IdType="pubmed">35877814</ArticleId></ArticleIdList></Reference><Reference><Citation>Vacchiano V, Mastrangelo A, Zenesini C, Baiardi S, Avoni P, Polischi B, Capellari S, Salvi F, Liguori R, Parchi P, BoReALS group (2023) Elevated plasma p-tau181 levels unrelated to Alzheimer&#x2019;s disease pathology in amyotrophic lateral sclerosis. J Neurol Neurosurg Psychiatry 94(6):428&#x2013;435. https://doi.org/10.1136/jnnp-2022-330709</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp-2022-330709</ArticleId><ArticleId IdType="pubmed">37012065</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilson EN, Young CB, Ramos Benitez J et al (2022) Performance of a fully-automated Lumipulse plasma phospho-tau181 assay for Alzheimer&#x2019;s disease. Alzheimers Res Ther 14(1):172. https://doi.org/10.1186/s13195-022-01116-2</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13195-022-01116-2</ArticleId><ArticleId IdType="pubmed">36371232</ArticleId><ArticleId IdType="pmc">9652927</ArticleId></ArticleIdList></Reference><Reference><Citation>Verde F, Milone I, Colombo E et al (2023) Phenotypic correlates of serum neurofilament light chain levels in amyotrophic lateral sclerosis. Front Aging Neurosci 15:1132808. https://doi.org/10.3389/fnagi.2023.1132808</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnagi.2023.1132808</ArticleId><ArticleId IdType="pubmed">37009451</ArticleId><ArticleId IdType="pmc">10050442</ArticleId></ArticleIdList></Reference><Reference><Citation>Roche JC, Rojas-Garcia R, Scott KM et al (2012) A proposed staging system for amyotrophic lateral sclerosis. Brain 135(Pt 3):847&#x2013;852. https://doi.org/10.1093/brain/awr351</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awr351</ArticleId><ArticleId IdType="pubmed">22271664</ArticleId><ArticleId IdType="pmc">3286327</ArticleId></ArticleIdList></Reference><Reference><Citation>Quinn C, Edmundson C, Dahodwala N, Elman L (2020) Reliable and efficient scale to assess upper motor neuron disease burden in amyotrophic lateral sclerosis. Muscle Nerve 61(4):508&#x2013;511. https://doi.org/10.1002/mus.26764</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/mus.26764</ArticleId><ArticleId IdType="pubmed">31743477</ArticleId></ArticleIdList></Reference><Reference><Citation>Colombo E, Doretti A, Scheveger F et al (2023) Correlation between clinical phenotype and electromyographic parameters in amyotrophic lateral sclerosis. J Neurol 270(1):511&#x2013;518. https://doi.org/10.1007/s00415-022-11404-4</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00415-022-11404-4</ArticleId><ArticleId IdType="pubmed">36183286</ArticleId></ArticleIdList></Reference><Reference><Citation>Levey AS, Stevens LA, Schmid CH et al (2009) A new equation to estimate glomerular filtration rate. Ann Intern Med 150(9):604&#x2013;612. https://doi.org/10.7326/0003-4819-150-9-200905050-00006</Citation><ArticleIdList><ArticleId IdType="doi">10.7326/0003-4819-150-9-200905050-00006</ArticleId><ArticleId IdType="pubmed">19414839</ArticleId><ArticleId IdType="pmc">2763564</ArticleId></ArticleIdList></Reference><Reference><Citation>Poletti B, Solca F, Carelli L et al (2016) The validation of the Italian Edinburgh Cognitive and Behavioural ALS Screen (ECAS). Amyotroph Lateral Scler Frontotemporal Degener 17(7&#x2013;8):489&#x2013;498. https://doi.org/10.1080/21678421.2016.1183679</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21678421.2016.1183679</ArticleId><ArticleId IdType="pubmed">27219526</ArticleId></ArticleIdList></Reference><Reference><Citation>Strong MJ, Abrahams S, Goldstein LH et al (2017) Amyotrophic lateral sclerosis - frontotemporal spectrum disorder (ALS-FTSD): Revised diagnostic criteria. Amyotroph Lateral Scler Frontotemporal Degener 18(3&#x2013;4):153&#x2013;174. https://doi.org/10.1080/21678421.2016.1267768</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21678421.2016.1267768</ArticleId><ArticleId IdType="pubmed">28054827</ArticleId><ArticleId IdType="pmc">7409990</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>